• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Partners taking aim at DED in American veterans


TearLab, MellingMedical reach an agreement to enhance early detection of dry eye disease in veterans.

TearLab Corp. and MellingMedical are teaming up to empower physicians to more effectively diagnose dry eye disease (DED) among veterans.

"We are excited to bring osmolarity testing to America's veterans and help support their patient care and therapy decisions," Chris Melling, founder and CEO of MellingMedical, said in a statement.

Established in more than 100 studies and publications and with over 20 million tests completed to date, the TearLab Osmolarity System aids physicians in the diagnosis of dry eye by providing precise, predictive, and objective results in 90 seconds.

Ophthalmology groups have deemed this test key in detecting significant ocular surface disease as part of the pre-operative workup.

"Osmolarity testing helps empower physicians with an objective and early detection of DED, and provides them with a faster feedback loop to evaluate the impact of therapeutic decisions over a period of weeks instead of months,1-2" said Adam Szaronos, Chief Commercial Officer of TearLab. "This partnership with MellingMedical now enables veterans and teaching hospitals across the US to access this technology for their patients."

TearLab’s Osmolarity System allows for objective and quantitative measurement of tear osmolarity, a biomarker of dry eye.



1. Sullivan BD, Crews LA, Sönmez B, et al. Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management. Cornea. 2012;31(9):1000-1008. doi: 10.1097/ICO.0b013e318242fd60.

2. Nelson JS, Farris RL. Sodium hyaluronate and polyvinyl alcohol artificial tear preparations. A comparison in patients with keratoconjunctivitis sicca. Arch Ophthalmol. 1988;106(4):484-487. doi: 10.1001/archopht.1988.01060130530029.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.